First Announcement

10th International Conference on Cachexia, Sarcopenia & Muscle Wasting

- Cachexia in Cancer, Heart Failure, COPD, CKD and Stroke
- Sarcopenia, Frailty and the Dysmobility Syndrome
- Pathophysiology and Epidemiology of Muscle Wasting
- Body Composition Assessments
- Screening, Diagnostic and Management
- Special Populations
- Clinical Trial Data

Rapid fire abstracts sessions
Young investigator awards
Late-breaking research and clinical abstract deadline: 30 September, 2017
Plenty of time for discussion

Follow us on www.cachexia.org

Rome
8-10 December 2017
Dear Colleague,

The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) is pleased to invite you to attend its first Updates Programme on Cachexia, Sarcopenia and Wasting Diseases that will be held on December 8-10, 2017, in Rome, Italy. As an international and multidisciplinary organization, the SCWD seeks to further research on cachexia, sarcopenia and muscle wasting in order to bring practical solutions to healthcare teams worldwide.

Since the first cachexia conference that took place in Berlin in 2000, over 2000 physicians from over 25 countries have attended our educational sessions. We expect this SCWD conference in 2017 to be a unique forum for all medical professionals dealing with muscle wasting in their disciplines and we look forward to meeting you in Rome.

We have already more than 180 abstracts and that is very encouraging. Looking forward to meeting you in Rome.

Yours sincerely,
John E. Morley
Stefan D. Anker

CHAIRMEN:
John E. Morley, St. Louis, MO, USA
Stefan D. Anker, Berlin, Germany

INTERNATIONAL SCIENTIFIC COMMITTEE:
Stefan D. Anker (President) – Berlin, Germany
John E. Morley – St. Louis, USA
William J. Evans – Durham, USA
Akio Inui – Kobe, Japan
Josep M. Argiles – Barcelona, Spain
Filippo Rossi-Fanelli – Rome, Italy
Vickie E. Baracos – Edmonton, Canada
Andrew Coats, Melbourne, Australia and Warwick, UK
Wolfram Doehner – Berlin, Germany
Luigi Ferrucci – Baltimore, USA
David J. Glass – Boston, USA
Aminah Jatoi – Rochester, USA
Kamyar Kalantar-Zadeh – Torrance, USA
Maurizio Muscaritoli - Rome, Italy
Florian Strasser – St. Gallen, Switzerland
Stephan von Haehling – Göttingen, Germany
### MORNING

**8:00-8:45**  | Special sessions: pre-registrations only

**Statistical Seminar**

**CHAIRS:** Jennifer Le-Rademacher, USA  
Jeffrey Crawford, USA

**Ken Fearon Career Café – Meet the Mentor**
Coordinated by Mitja Lainscak, Slovenia

**A 9:00-10:50**  | Opening SESSION 1

**CHAIRS:** Stefan Anker, Germany  
Maurizio Muscaritoli, Italy  
Filippo Rossi-Fanelli, Italy

Welcome by the Chairs

"Hippocrates" clinical science key note lecture: Role of mitochondria in age-related muscle impairment  
Luigi Ferrucci, USA

Frailty in 2017  
Bruno Vellas, France

Sex differences in cachexia, sarcopenia and wasting disorders  
James Carson, USA

Research gaps from the NCI consensus  
Joanne Elena, USA

A payer perspective on cachexia and sarcopenia  
Bette Caan, USA

**10:50-11:20**  | Coffee break

**B 11:20-13:00**  | Opening SESSION 2

**CHAIRS:** Josep Argiles, Spain  
Andrea Bonetto, USA

"Prometheus" basic science key note lecture  
William Evans, USA

News from proteomic and gene expression data related to aging and cachexia  
H. Alexander Ebhardt, Ireland

Cause of death in sarcopenia & cachexia  
Stefan Anker, Germany

Metabolic modulation by nutrients  
Maurizio Muscaritoli, Italy

Precision medicine for cachexia  
John Morley, USA

**13:15-14:15**  | Lunch seminar(s)

### AFTERNOON

**14:30-16:00**  | Translating sarcopenia research across diseases

**CHAIR:** Zudin Puthucheary, UK

**Skeletal muscle ammonia metabolism in non-hepato pathological disease**  
Srinivasan Dasarathy, USA

**Kidney dysfunction as a contribution to muscle wasting in chronic illness**  
Giacomo Garibotto, Italy

**Separating inflammation and deconditioning as contributors to muscle wasting in COPD**  
Paul Greenhaff, UK

**Molecular signaling homology across muscle wasting conditions**  
Dario Coletti, Italy

**Sarcopenia in 2017 – what is new?**  
Francesco Landi, Italy

**16:00-17:00**  | Coffee break & science

**16:05-16:55**  | Rapid Fire Abstract Session 1

**CHAIRS:** Andrea Bonetto, Italy  
David Waning, USA

**16:10-16:50**  | Poster Viewing Session 1

**17:00-18:30**  | 2 PARALLEL SESSIONS

**E 17:30-18:00**  | Biological versus numerical aging

**CHAIRS:**

**DNA methylation and the biological clock**  
TBD

**Frailty scoring: biological aging phenotypes in the critically ill survivors**  
Zudin Puthucheary, UK

**Relationship between aging and physiological function**  
Stephen Harridge, UK

**Nutritional status and satiety and the interaction with biological ageing**  
Alessandro Laviano, Italy

**Panel discussion**

**18:30-19:30**  | Welcome reception & poster viewing

**2 PARALLEL SESSIONS**

**D 16:05-16:55**  | Mechanisms of muscle wasting

**CHAIRS:** Denis Guttridge, USA  
Paola Costelli, Italy

**Autophagy dysregulation in muscle stem cells during aging**  
Marco Sandri, Italy

**Mechanisms of pathological replacement of skeletal muscle tissue with adipose tissue**  
Renata Dmitrieva, Russia

**The role of lysosomes in body wasting**  
Jochen Springer, Germany

**ER stress and UPR in skeletal muscle health and disease**  
Ashok Kumar, USA

**Role of JAK/STAT signalling in muscle wasting**  
Teresa Zimmers, USA

**Mitochondrial impairment in skeletal muscle wasting**  
Antonio Zorzano, Spain

**F 16:00-16:55**  | Tumor-secreted factors, cytokines and concepts of cachexia development

**CHAIRS:** Didier Attaix, France  
Giovanni Mantovani, Italy

**Metabolic regulators of cachexia in cancer**  
Pankaj Singh, USA

**New insights on cancer cachexia**  
Denis Guttridge, USA

**The muscle gp130 receptor’s role for cancer-induced anabolic resistance: therapeutic implications for improving cancer survival**  
James Carson, USA

**Mechanisms of muscle atrophy and hypertrophy**  
David Glass, USA

**MIC-1 / GDF-15**  
Samuel Breit, Australia
### Morning

#### 7:45-8:45  Morning symposia
- **Recent developments and updates on CT imaging for body composition analysis**
  - **CHAIRS:** Andrew Coats, UK  
  Joanne Elena, USA
  - Methodological standards of CT imaging and its use as endpoint in clinical trials  
  Vickie Baracos, Canada
  - Clinical practice of anti-cancer treatment dose adaption by muscle mass data  
  Florian Strasser, Switzerland
  - CT based muscle radioactivity as prognostic marker  
  Sami Antoun, France
  - CT based assessment of muscle mass in clinical trials: the reality check and industry view  
  TBD
  - CT imaging in phase 2/3 trials – what do the regulators expect to see?  
  TBD
  - Panel discussion

#### 8:00-8:45  Special sessions: pre-registrations only
- **How to assess muscle mass and function using non-imaging techniques**
  - **CHAIRS:** Stephan von Haehling, Germany  
  William Evans, USA
  - The need for accurate assessment of body composition in infants and children  
  Daniel Marks, USA
  - The D3-creatine dilution method: methodology & new data  
  Eric Orwoll, USA
  - MoS: Longitudinal observational trial in older men – body composition and outcomes  
  Peggy Cawthon, USA
  - SPRINT-T – update 2017  
  Roberto Bernabei, Italy
  - Panel discussion

#### 9:00-10:30  3 PARALLEL SESSIONS

##### G
- **Recent developments and updates on CT imaging for body composition analysis**
  - **CHAIRS:** Andrew Coats, UK  
  Joanne Elena, USA
  - Methodological standards of CT imaging and its use as endpoint in clinical trials  
  Vickie Baracos, Canada
  - Clinical practice of anti-cancer treatment dose adaption by muscle mass data  
  Florian Strasser, Switzerland
  - CT based muscle radioactivity as prognostic marker  
  Sami Antoun, France
  - CT based assessment of muscle mass in clinical trials: the reality check and industry view  
  TBD
  - CT imaging in phase 2/3 trials – what do the regulators expect to see?  
  TBD
  - Panel discussion

##### H
- **How to assess muscle mass and function using non-imaging techniques**
  - **CHAIRS:** Stephan von Haehling, Germany  
  William Evans, USA
  - The need for accurate assessment of body composition in infants and children  
  Daniel Marks, USA
  - The D3-creatine dilution method: methodology & new data  
  Eric Orwoll, USA
  - MoS: Longitudinal observational trial in older men – body composition and outcomes  
  Peggy Cawthon, USA
  - SPRINT-T – update 2017  
  Roberto Bernabei, Italy
  - Panel discussion

##### I
- **Young investigators awards session**
  - **Clinical Basic**
  - **CHAIRS:** Luigi Ferrucci, USA  
  Alessandro Laviano, Italy
  - Judges: Giovanni Mantovani, Italy  
  Teresa Zimmers, USA  
  Samuel Breit, Australia
  - Malnutrition and Cachexia in cancer patients at first medical oncology visit  
  Maurizio Muscaritoli, Italy
  - Micronutrients in sarcopenia and age-related physical decline  
  Jerome Feige, Switzerland
  - Interaction exercise and nutrition in sarcopenia  
  Roger Fielding, USA
  - The efficacy of a novel oral nutrition supplement in tackling sarcopenia in the elderly  
  Pol Grootswagers, The Netherlands
  - Proteins to treat sarcopenia  
  Jürgen Bauer, Germany
  - Trial experience in wasting disorders using nutritional approaches  
  Jann Arends, Germany

#### 10:30-11:30  Coffee break & science

#### 10:35-11:25  Poster Viewing Session 2

#### 10:40-11:20  Rapid Fire Abstract Session 2

#### 11:30-13:00  3 PARALLEL SESSIONS

##### J
- **Muscle loss in liver diseases**
  - **CHAIRS:** TBD
  - Epidemiology and clinical significance of sarcopenia in liver cirrhosis  
  Mathias Plauth, Germany
  - Significance of sarcopenia and sarcopenic obesity in fatty liver  
  Manuela Merli, Italy
  - Molecular mechanisms of sarcopenia in liver cirrhosis  
  Michela Giusto, Italy
  - Role of Hif in muscle wasting  
  Steven Olde Damink, The Netherlands
  - Treatment approaches for muscle wasting in liver cirrhosis  
  Srinivasan Dasarathy, USA

##### K
- **Cachexia: not just muscle**
  - **CHAIRS:** James Carson, USA  
  Jochen Springer, Germany
  - The bone-muscle cross-talk  
  David Waning, USA
  - Adipogenic drive in cancer-induced muscle wasting  
  Paola Costelli, Italy
  - Energy metabolism, mitochondria and cachexia in COPD  
  Annemie Schols, The Netherlands
  - Metabolic regulation of fat in cancer cachexia  
  Stefan Herzig, Germany
  - Protecting fat to gain muscle – a possible new therapeutic concept?  
  TBD

##### L
- **Nutritional approaches to combat sarcopenia & cachexia**
  - **CHAIR:** Nicolaas Deutz, USA
  - Malnutrition and Cachexia in cancer patients at first medical oncology visit  
  Maurizio Muscaritoli, Italy
  - Micronutrients in sarcopenia and age-related physical decline  
  Jerome Feige, Switzerland
  - Interaction exercise and nutrition in sarcopenia  
  Roger Fielding, USA
  - The efficacy of a novel oral nutrition supplement in tackling sarcopenia in the elderly  
  Pol Grootswagers, The Netherlands
  - Proteins to treat sarcopenia  
  Jürgen Bauer, Germany
  - Trial experience in wasting disorders using nutritional approaches  
  Jann Arends, Germany

#### 13:15-14:15  Lunch seminar(s)
### Models of cachexia

**CHAIRS:** Stefan Herzig, Germany  
Jochen Springer, Germany

- Human xenografts as a suitable model for studying cancer cachexia  
  Andrew Judge, USA
- Modeling cachexia: the impact of anti-neoplastic therapy  
  Andrea Bonetto, USA
- Experimental models for aging and sarcopenia  
  TBD
- New experimental model of cancer cachexia & kidney disease  
  Dan Marks, USA
- Large animal models of human cachexia: update 2017  
  Lisa Freeman, USA

### Cachexia at its worst

**CHAIRS:** Vicky Baracos, Canada  
Stephan von Haehling, Germany

- Diagnostic criteria for the classification of cancer-associated weight loss  
  Egidio Del Fabbro, USA
- Wasting of muscle involved in swallowing and mastication  
  Florian Strasser, Switzerland
- Diagnosis and management of oropharyngeal dysphagia  
  Pere Clavé, Spain
- Treating shortness of breath in advanced cancer cachexia – the muscle hypothesis  
  Andrew Coats, UK
- Palliative care and anabolic therapies  
  Aminah Jatoi, USA

### Targeting skeletal muscle – from research to clinical development

**CHAIRS:** TBD

- Biopsies of skeletal muscle – a source of new understanding  
  Volker Adams, Germany
- Muscle satellite cells  
  Mariz Vainzof, Brazil
- Diabetes and muscle  
  Leocadio Rodríguez Mañas, Spain
- Gene therapy approaches to treat cancer cachexia  
  Paul Gregorevic, Australia
- Cachexia & sarcopenia – how to develop and get approved drugs there  
  Giuseppe Rosano, UK

### Targeting skeletal muscle – from research to clinical development

**CHAIRS:** TBD

- Biopsies of skeletal muscle – a source of new understanding  
  Volker Adams, Germany
- Muscle satellite cells  
  Mariz Vainzof, Brazil
- Diabetes and muscle  
  Leocadio Rodríguez Mañas, Spain
- Gene therapy approaches to treat cancer cachexia  
  Paul Gregorevic, Australia
- Cachexia & sarcopenia – how to develop and get approved drugs there  
  Giuseppe Rosano, UK

### Rehabilitation in advanced elderly cancer patients with cachexia

**CHAIRS:** Paolo Bossi, Italy  
Florian Strasser, Switzerland

- Muscle of the elderly and physical activity: balancing over- and undertreatment  
  Francesco Landi, Italy
- Exercise training as an effective tool to improve cancer-induced wasting muscle  
  Fabio Penna, Italy
- Current trials in cancer studying physical activity, endurance and strength training  
  Vivianne Hess, Switzerland
- Rehabilitative-geriatric interventions in elderly advanced cancer patients: who will respond?  
  Pierre Soubeyran, France
- Anabolic interventions in men and women: is there emerging evidence?  
  Hans Wildiers, Belgium
- What can cancer cachexia rehabilitation trials learn from critical care rehabilitation?  
  Linda Denehy, Australia

### Potential treatments for muscle wasting and cachexia

**CHAIR:** Volker Adams, Germany  
Marco Sandri, Italy

- MEK inhibitors as potential tools to improve cancer-induced muscle wasting  
  Erin Talbert, USA
- MAGIC-F1 modulations to improve myogenesis  
  Maurilio Sampaolesi, Italy
- Irisin, vitamin D and muscle-bone interactions  
  Maria Grano, Italy
- Drugs modifying catabolic/anabolic balance: ACE inhibitors + beta-blockers  
  Mitja Lainscak, Slovenia
- What else is new – update from the big pharma pipeline  
  David Glass, Switzerland

### Muscle wasting and cachexia in chronic illnesses – update 2017

**CHAIRS:** Annemie Schols, The Netherlands  
Giacomo Garibotto, Italy

- COPD  
  TBD
- Chronic heart failure  
  Stephan von Haehling, Germany
- Chronic kidney disease failure  
  Robert Mak, USA
- Stroke  
  Wolfram Doehner, Germany
- Cancer  
  Jeffrey Crawford, USA
<table>
<thead>
<tr>
<th>7:45-8:45</th>
<th>Morning Symposia</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45-9:45</td>
<td>Session of the Journal of Cachexia, Sarcopenia and Muscle (JCSM)</td>
</tr>
<tr>
<td>9:00-10:15</td>
<td>2 PARALLEL SESSIONS</td>
</tr>
<tr>
<td><strong>S</strong></td>
<td>Imaging methods for assessing muscle mass</td>
</tr>
<tr>
<td><strong>CHAIRS:</strong> Vickie Baracos, Canada</td>
<td><strong>CHAIRS:</strong> Bruno Vellas, France</td>
</tr>
<tr>
<td>Steven Heymsfield, USA</td>
<td>John Morley, USA</td>
</tr>
<tr>
<td>Body impedance</td>
<td>The physical frailty phenotype</td>
</tr>
<tr>
<td>Maria-Christina Gonzalez, Brazil</td>
<td>TBD</td>
</tr>
<tr>
<td>Cross-sectional: CT or MRI</td>
<td>Treatment trials for frailty</td>
</tr>
<tr>
<td>Vickie Baracos, Canada</td>
<td>TBD</td>
</tr>
<tr>
<td>Quadriceps contractile volume by MRI</td>
<td>Validating SARC-F</td>
</tr>
<tr>
<td>Jean Maden-Wilkinson, UK</td>
<td>Jean Woo, Hong Kong</td>
</tr>
<tr>
<td>Ultra-sound methods</td>
<td>The role of T2DM in the development of sarcopenia and frailty</td>
</tr>
<tr>
<td>Thiago Gonzalez Barbosa-Silva, Brazil</td>
<td>Theodore Malmstrom, USA</td>
</tr>
<tr>
<td>Panel discussion</td>
<td>Treating sarcopenia</td>
</tr>
<tr>
<td>Tommy Cederholm, Sweden</td>
<td></td>
</tr>
<tr>
<td>10:15-11:15</td>
<td>Coffee break &amp; science</td>
</tr>
<tr>
<td>10:20-11:10</td>
<td>Poster Viewing Session 4</td>
</tr>
<tr>
<td>11:15-12:45</td>
<td>2 PARALLEL SESSIONS</td>
</tr>
<tr>
<td><strong>U</strong></td>
<td>Clinical trials in progress</td>
</tr>
<tr>
<td><strong>CHAIRS:</strong> Aminah Jatoi, USA</td>
<td><strong>CHAIRS:</strong> William Evans, USA</td>
</tr>
<tr>
<td>Andrew Coats, UK</td>
<td></td>
</tr>
<tr>
<td>TBD</td>
<td>TBD</td>
</tr>
<tr>
<td>Patrick Lacarin, France</td>
<td></td>
</tr>
<tr>
<td>Peptamen for weight loss</td>
<td></td>
</tr>
<tr>
<td>Andrew Hendi baf, USA</td>
<td></td>
</tr>
<tr>
<td>Cannabis for cancer-associated weight loss</td>
<td></td>
</tr>
<tr>
<td>Moran Grinberg, Israel</td>
<td></td>
</tr>
<tr>
<td>Sildenafil for cholangiocarcinoma or pancreas cancer: rationale and study design</td>
<td></td>
</tr>
<tr>
<td>Melinda Sheffield Moore, USA</td>
<td>TBD</td>
</tr>
<tr>
<td>12:45-13:15</td>
<td>Coffee break</td>
</tr>
<tr>
<td>13:15-14:45</td>
<td>2 PARALLEL SESSIONS</td>
</tr>
<tr>
<td><strong>W</strong></td>
<td>Late breaking clinical trials &amp; trial updates</td>
</tr>
<tr>
<td><strong>CHAIRS:</strong> Andrew Coats, UK</td>
<td><strong>CHAIRS:</strong> Filippo Rossi-Fanelli, Italy</td>
</tr>
<tr>
<td>Stefan Anker, Germany</td>
<td></td>
</tr>
<tr>
<td>TBD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45-15:45</td>
<td>Highlights of the congress</td>
</tr>
<tr>
<td><strong>CHAIRS:</strong> Stefan Anker, Germany - Maurizio Muscaritoli, Italy - Annemie Schols, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Basic science &amp; pathophysiology</td>
<td></td>
</tr>
<tr>
<td>Annemie Schols, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Body composition</td>
<td></td>
</tr>
<tr>
<td>Steven Heymsfield, USA</td>
<td></td>
</tr>
<tr>
<td>Sarcopenia</td>
<td></td>
</tr>
<tr>
<td>Stephan von Haehling, Germany</td>
<td></td>
</tr>
<tr>
<td>Cachexia in chronic illness</td>
<td></td>
</tr>
<tr>
<td>TBD</td>
<td></td>
</tr>
<tr>
<td>Nutrition treatment</td>
<td></td>
</tr>
<tr>
<td>Roger Fielding, USA</td>
<td></td>
</tr>
<tr>
<td>Treatment of cachexia</td>
<td></td>
</tr>
<tr>
<td>Andrew Coats, UK</td>
<td></td>
</tr>
<tr>
<td>16:45-15:45</td>
<td>Awards Ceremony</td>
</tr>
<tr>
<td>Best Poster Award</td>
<td>Young Investigators Award</td>
</tr>
</tbody>
</table>
EDUCATIONAL OBJECTIVES:
Following this activity, the audience will be able to:
1. Review the latest information about the pathophysiology of muscle wasting and its epidemiology.
2. Screen for and diagnose cachexia, sarcopenia, frailty and dysmobility resulting from the following diseases or chronic conditions: cancer, cardiovascular disease, COPD, CKD, dementia/Alzheimer’s disease, diabetes, infectious diseases, stroke and aging.
3. Develop appropriate management programs for patients across the continuum of care.

TARGET AUDIENCE:
Internists, oncologists, cardiologists, gerontologists, palliative care specialists, primary care physicians and nurses.